아겐스 ADR ARGX 주가

핵심 리스크

특이 리스크 신호는 없어요 (희석·거래정지·공매도·저유통 등).

당일 등락

-14%

시가 갭

—

당일 고가 대비

—

오늘 거래정지

없음

평소 회전율 (플로트/일)

—

오늘 거래량

—

평소 회전율 = 10일 평균 거래량 ÷ 유통주식. 높을수록 손바뀜이 활발해 단타가 잘 붙어요. 오늘 거래량은 KIS 실시간이 붙으면 전체 거래소 통합, 아니면 무료 피드의 부분 집계예요(옆에 어느 쪽인지 적혀 있어요).

체결가 등락으로 매수/매도 방향을 추정한 근사치예요(tick rule). 규모는 이 종목 자체 거래 분포 기준 — 초대형 = 상위 5% 큰 체결. 최근 정규장 기준.

10일 평균 거래량

—

3개월 평균 거래량

—

발행주식수

6,256만주

유통주식 (Float)

—

52주 최고가

—

52주 최저가

—

베타

—

PER (TTM)

—

PBR

—

최근 18개월간 희석 관련 공시가 없어요.

0-100점이에요. 60점을 넘으면 스퀴즈 가능성이 있어요.

공매도 잔고 (유통 대비)

+2.1%

상환일수 (DTC)

6.3일

공매도 거래비중

+41.2%

차입 비용

+0.3%

상환일수 (DTC)

6.3일

당일 공매도 비중

41%

차입료 (CTB)

0%

대여 가능

150K주

• Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysisbenzinga2시간 전neutral
• Argenx Will Discontinue Phase 3 UNITY Study Of Efgartigimod SC In Sjögren's Disease After IDMC Recommends Stopping For Futility At Interim Analysis; No New Safety Signals Identifiedbenzinga9시간 전neutral
• Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Developmentbenzinga9시간 전호재
• argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseStockTitan10시간 전neutral
• argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseStockTitan10시간 전호재
• Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targetsbenzinga어제neutral
• Argenx Says VYVGART Showed Continued Improvement In Ocular Myasthenia Gravis, Sustained One-Year Efficacy In Antibody-Negative Generalized MGbenzinga1주 전neutral
• argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular PipelineStockTitan1주 전neutral
• Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Todaybenzinga1주 전neutral
• Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Targetbenzinga2026.09.08 22:23neutral

1. 뉴스2시간 전 · benzinga

   Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis

2. 뉴스9시간 전 · benzinga

   Argenx Will Discontinue Phase 3 UNITY Study Of Efgartigimod SC In Sjögren's Disease After IDMC Recommends Stopping For Futility At Interim Analysis; No New Safety Signals Identified

3. 뉴스9시간 전 · benzinga

   Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development

4. 뉴스10시간 전 · StockTitan

   argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

5. 뉴스10시간 전 · StockTitan

   argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

6. 뉴스어제 · benzinga

   Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets

7. 뉴스1주 전 · benzinga

   Argenx Says VYVGART Showed Continued Improvement In Ocular Myasthenia Gravis, Sustained One-Year Efficacy In Antibody-Negative Generalized MG

8. 뉴스1주 전 · StockTitan

   argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

9. 뉴스1주 전 · benzinga

   Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

10. 뉴스2026.09.08 22:23 · benzinga

    Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target

11. 뉴스2026.09.05 05:15 · benzinga

    Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

12. 뉴스2026.09.03 22:17 · benzinga

    Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target

13. 뉴스2026.08.31 23:36 · benzinga

    Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1250

14. 뉴스2026.08.27 01:02 · benzinga

    UBS Upgrades argenx to Buy, Raises Price Target to $1400

불러오는 중…

분류

분류·메모를 달면 자동으로 관심종목에 담겨요.

불러오는 중…